TNFRSF4 and neoplasm: Given that OX40 triggering can potently stimulate T cells and potentially block/eliminate regulatory T cells, OX40 agonists have been investigated in multiple preclinical tumor models [31]–[34] and an anti-human OX40 monoclonal antibody is currently being evaluated in clinical trials (Clinical trial registration numbers NCT01303705, NCT01416844, NCT01862900, NCT01644968 and NCT01642290).